Cyclacel appoints Nicholas Bacopoulos, Ph.D. to Board of Directors
Cyclacel Pharmaceuticals, Inc. announced the appointment of Nicholas Bacopoulos, Ph.D., to its Board of Directors. Dr. Bacopoulos has more than 25 years of experience at leading biotechnology and pharmaceutical companies, serving in multiple executive positions and managing the discovery and development of novel anticancer agents.
Dr. Bacopoulos’ previous leadership roles include CEO and President of Aton Pharma, where he led the development of Zolinza®, approved for the treatment of cutaneous T-cell lymphoma. Aton was subsequently acquired by Merck. He was previously President and Head of R&D at OSI Pharmaceuticals, where he was involved with the global development of Tarceva®, approved for the treatment of non-small cell lung cancer and pancreatic cancer.
Dr. Bacopoulos also worked for 17 years at Pfizer, where he held senior positions within Pfizer Central Research and Corporate Strategic Planning. He led the company's Cancer and Neuroscience Research groups, which developed several marketed drugs, including Geodon® and Zoloft®, and produced a significant pipeline of oncology drug candidates, several of which are in clinical trials.
Dr. Bacopoulos is currently a consultant to biotech and pharmaceutical companies. He also serves on the Board of Directors of Mersana Therapeutics, Inc. and Medexis Biotech, S.A., both privately-held biotechnology companies. He received his B.A. degree from Cornell College and his Ph.D. from the University of Iowa. He completed additional coursework and obtained a postdoctoral fellowship at Yale University School of Medicine.
Other news from the department people
